scholarly journals Effects of diabetes compensation by various classes of antihyperglycemic agents on endovascular intervention outcomes in patients with type 2 diabetes mellitus

2014 ◽  
Vol 17 (1) ◽  
pp. 34-40 ◽  
Author(s):  
Marina Sergeevna Michurova ◽  
Irina Vladimirovna Kononenko ◽  
Olga Mikhailovna Smirnova ◽  
Victor Yur'evich Kalashnikov
Keyword(s):  
Diabetes Mellitus ◽  
Endovascular Intervention ◽  
Percutaneous Coronary Interventions ◽  
Antihyperglycemic Agents ◽  
Current Review ◽  
Percutaneous Coronary ◽  
Patients With Diabetes ◽  
Drug Eluting ◽  
Repeated Revascularization

Introduction of drug-eluting stents for percutaneous coronary interventions opened novel options for treating coronary heart disease (CHD) in patients with diabetes mellitus. However, mortality and myocardial infarction rates are still higher among diabetes patients. They also require repeated revascularization of the target vessel more often than euglycemic individuals do. Current review discusses possible effects of diabetes compensation by various classes of antihyperglycemic agents on endovascular intervention outcomes.

scholarly journals Patient-tailored Drug-eluting Stent Choice – A Solution for Patients with Diabetes

2015 ◽  
Vol 10 (3) ◽  
pp. 158
Author(s):  
Roxana Mehran ◽  
Antonio Colombo ◽  
Pieter Stella ◽  
Rafael Romaguera ◽  
Gennaro Sardella ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Unmet Needs ◽  
Dual Antiplatelet Therapy ◽  
Drug Eluting Stents ◽  
Drug Eluting Stent ◽  
Percutaneous Coronary Interventions ◽  
Improved Outcomes ◽  
Percutaneous Coronary ◽  
Patients With Diabetes ◽  
Drug Eluting

Although second-generation drug-eluting stents (DES) have improved outcomes in percutaneous coronary interventions (PCIs), important unmet needs remain. Two symposia at EuroPCR 2015 focused on two challenging scenarios. First, patients with diabetes mellitus (DM) have generally inferior outcomes following PCI. The Cre8™ stent (manufactured by CID Spa, member of Alvimedica Group) has shown unique efficacy in subpopulations of patients with DM during clinical trials. A live case in a patient with diabetes illustrated the challenges of complex multivessel disease. Second, optimising stent selection towards devices that have demonstrated complete and early endothelialisation offers the potential to reduce the duration of dual antiplatelet therapy. The Cre8™ DES features a polymer-free platform and has been associated with low rates of in-stent thrombosis.

scholarly journals Contrast-induced nephropathy in cardiology practice: Risk factors and approaches to prevention

2012 ◽  
Vol 18 (3) ◽  
pp. 222-227
Author(s):  
YU. F. Salakhova ◽  
D. V. Duplyakov ◽  
E. R. Perunova ◽  
S. E. Burnazyan ◽  
E. I. Bazhenova ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Risk Factors ◽  
Filtration Rate ◽  
Percutaneous Coronary Interventions ◽  
Contrast Induced Nephropathy ◽  
Gault Formula ◽  
Percutaneous Coronary ◽  
Initial Decrease ◽  
Patients With Diabetes ◽  
Design And Methods

Objective. To study the incidence and risk factors of contrast-induced nephropathy (CIN) resulted from percutaneous coronary interventions in cardiology practice. Design and methods. Retrospective analysis of 100 history cases of patients aged 37-73 years (mean age 56,1 ± 6,0 years) was preformed. 0mnipac-350 was used as a contrast agent during angiography. Glomerular filtration rate (GFR) was assessed by Cockroft-Gault formula before and 48 hours after the intervention. The patients were divided into 2 groups depending on the type of intervention: the first group included the patients with planned intervention and the second — with urgent endovascular intervention. Results. In the first group 3,0 % (n = 2) patients developed CIN, and one case was registered (2,95 %) in the second group. It developed in patients with initial decrease of GFR, in patients with diabetes mellitus and with the combination of both factors.

Sign in / Sign up

Export Citation Format

Share Document